We conducted a randomized phase I trial of carcinoembryonic antigen (CEA) peptide (CAP1-6D)/Montanide/GM-CSF-vaccine in 19 pancreatic cancer patients. The gene discussed is CEACAM5; the disease is familial pancreatic carcinoma.